ADAM10 Mediates Trastuzumab Resistance and is Correlated with Survival in HER2 Positive Breast Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Jun 23

PMID 24952873

Citations 45

Authors

Katharina Feldinger

Daniele Generali

Gabriela Kramer-Marek

Merel Gijsen

T B Ng

Jack Ho Wong

Carla Strina

Mariarosa Cappelletti

Daniele Andreis

Ji-Liang Li

Esther Bridges

Helen Turley

Russell Leek

Ioannis Roxanis

Jacek Capala

Gillian Murphy

Adrian L Harris

Anthony Kong

Affiliations

Soon will be listed here.

Abstract

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside ADAM17, ADAM10 is the other well characterized ADAM protease responsible for HER ligand shedding. Therefore, we studied the role of ADAM10 in relation to trastuzumab treatment and resistance in HER2 positive breast cancer. ADAM10 expression was assessed in HER2 positive breast cancer cell lines and xenograft mice treated with trastuzumab. Trastuzumab treatment increased ADAM10 levels in HER2 positive breast cancer cells (p ≤ 0.001 in BT474; p ≤ 0.01 in SKBR3) and in vivo (p ≤ 0.0001) compared to control, correlating with a decrease in PKB phosphorylation. ADAM10 inhibition or knockdown enhanced trastuzumab response in naïve and trastuzumab resistant breast cancer cells. Trastuzumab monotherapy upregulated ADAM10 (p ≤ 0.05); and higher pre-treatment ADAM10 levels correlated with decreased clinical response (p ≤ 0.05) at day 21 in HER2 positive breast cancer patients undergoing a trastuzumab treatment window study. Higher ADAM10 levels correlated with poorer relapse-free survival (p ≤ 0.01) in a cohort of HER2 positive breast cancer patients. Our studies implicate a role of ADAM10 in acquired resistance to trastuzumab and establish ADAM10 as a therapeutic target and a potential biomarker for HER2 positive breast cancer patients.

Citing Articles

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review.

Zhong H, Zhou Z, Wang H, Wang R, Shen K, Huang R Int J Mol Sci. 2025; 25(24.

PMID: 39769140 PMC: 11677710. DOI: 10.3390/ijms252413376.

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C Cancer Commun (Lond). 2024; 45(1):68-73.

PMID: 39582148 PMC: 11758155. DOI: 10.1002/cac2.12632.

Identification of key genes and pathways involved in T-DM1-resistance in OE-19 esophageal cancer cells through bioinformatics analysis.

Yazdani F, Mottaghi-Dastjerdi N, Shahbazi B, Ahmadi K, Ghorbani A, Soltany-Rezaee-Rad M Heliyon. 2024; 10(18):e37451.

PMID: 39309859 PMC: 11415672. DOI: 10.1016/j.heliyon.2024.e37451.

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.

Arshad M, Azad A, Chan P, Vigneswara V, Feldinger K, Nafi S Br J Cancer. 2024; 130(12):1990-2002.

PMID: 38600326 PMC: 11182766. DOI: 10.1038/s41416-024-02665-z.

Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo.

Bahrami E, Schmid J, Jurinovic V, Becker M, Wirth A, Ludwig R Mol Cancer. 2023; 22(1):107.

PMID: 37422628 PMC: 10329331. DOI: 10.1186/s12943-023-01803-0.

References

Ni Y, Wang N, Cao D, Sachan N, Morris D, Gerard R . FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci U S A. 2007; 104(51):20517-22. PMC: 2154463. DOI: 10.1073/pnas.0610290104. View

Hudis C, Barlow W, Costantino J, Gray R, Pritchard K, Chapman J . Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25(15):2127-32. DOI: 10.1200/JCO.2006.10.3523. View

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K . Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4(10):1592-605. PMC: 3858548. DOI: 10.18632/oncotarget.1148. View

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

Zhang X, Gureasko J, Shen K, Cole P, Kuriyan J . An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006; 125(6):1137-49. DOI: 10.1016/j.cell.2006.05.013. View

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum R . Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5(3):187-94. PMC: 3341681. View

McCulloch D, Akl P, Samaratunga H, Herington A, Odorico D . Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res. 2004; 10(1 Pt 1):314-23. DOI: 10.1158/1078-0432.ccr-0846-3. View

Liu P, Liu X, Li Y, Covington M, Wynn R, Huber R . Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther. 2006; 5(6):657-64. DOI: 10.4161/cbt.5.6.2708. View

Baselga J, Swain S . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9(7):463-75. DOI: 10.1038/nrc2656. View

10.

Reiss K, Maretzky T, Ludwig A, Tousseyn T, De Strooper B, Hartmann D . ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 2005; 24(4):742-52. PMC: 549617. DOI: 10.1038/sj.emboj.7600548. View

11.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

12.

Osipo C, Patel P, Rizzo P, Clementz A, Hao L, Golde T . ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008; 27(37):5019-32. DOI: 10.1038/onc.2008.149. View

13.

Linggi B, Carpenter G . ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006; 16(12):649-56. DOI: 10.1016/j.tcb.2006.10.008. View

14.

Wang Y, Ye Z, Li L, Zhao Z, Shao Q, Tao H . ADAM 10 is associated with gastric cancer progression and prognosis of patients. J Surg Oncol. 2011; 103(2):116-23. DOI: 10.1002/jso.21781. View

15.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

16.

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

17.

McGowan P, Ryan B, Hill A, McDermott E, OHiggins N, Duffy M . ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007; 13(8):2335-43. DOI: 10.1158/1078-0432.CCR-06-2092. View

18.

Bottini A, Berruti A, Bersiga A, Brizzi M, Brunelli A, Gorzegno G . p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000; 6(7):2751-8. View

19.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

20.

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E . Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10(1):39-50. PMC: 4451119. DOI: 10.1016/j.ccr.2006.05.024. View